Correction: Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
Similar Items
-
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study
by: Thorir Einarsson Long, et al.
Published: (2022-09-01) -
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies
by: Sæmundur Rögnvaldsson, et al.
Published: (2021-05-01) -
The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study
by: Jón Þórir Óskarsson, et al.
Published: (2024-12-01) -
Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study
by: Aðalbjörg Ýr Sigurbergsdóttir, et al.
Published: (2023-07-01) -
P894: INFECTION RISK BEFORE DIAGNOSIS OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: RESULTS FROM THE SCREENED POPULATION-BASED ISTOPMM STUDY
by: Marina Ros Levy, et al.
Published: (2023-08-01)